STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium
STC-15 is the first METTL3 inhibitor to enter clinical development
Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients
9 October 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it will be presenting a poster on the ongoing Phase 1 trial with its lead METTL3 RNA methyltransferase inhibitor, STC-15, at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, held in Barcelona, Spain, from 23-25 October 2024.
STC-15 is a potent and selective oral small molecule that inhibits METTL3 and is the first molecule specifically targeting an RNA methyltransferase enzyme in clinical development.
The presentation entitled, ‘First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies’, will detail results across its four active dose ranges, as well as pharmacological activity, biomarker analysis data and clinical responses.
Oliver Rausch, Chief Scientific Officer at STORM Therapeutics, said: “The data generated show encouraging signs of clinical activity, promising biomarker data and significant reductions in methylated polyA-RNA in blood samples from all cohorts, demonstrating METTL3 target engagement and rapid PD effect. As our ongoing study continues, we look forward to advancing STC-15 into later-stage studies.”
Details of the poster presentation are as follow:
Poster Title: First results of a Phase 1 study evaluating safety, PK, PD and clinical activity of STC-15, a METTL3 inhibitor, in patients with advanced malignancies
Presenter: Jordi Rodon, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX
Authors: Jordi Rodon1, Justin C Moser2, Kyriakos P. Papadopoulos3, Yaara Ofir-Rosenfeld4, Hendrik Weisser4, Melinda Snyder4, Tess Schmalbach4, Tess Barker4, Deepa Deshpande4, Ben Skead4, Doug Hester2, Nidhi Sheth2, Pamela Saldana Leon1, Edwin Blanco-Cepeda3, Oliver Rausch4, Josefin-Beate Holz4
Session Title: New therapies in immuno oncology
Session Date and Time: Friday October 25th, 2024, 09:00 - 15:00 CEST
Location: Exhibition Hall
Catalog Number: 451
Presentation Number: PB439
1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX;
2HonorHealth Research Institute, Scottsdale, AZ;
3START San Antonio, San Antonio, TX;
4Storm Therapeutics Ltd, Cambridge, United Kingdom
CONTACTS:
STORM Therapeutics Ltd
Tel: +44 (0)1223 804174
info@stormtherapeutics.com
Optimum Strategic Communications
Hana Malik, Zoe Bolt, Elena Bates
Tel: +44 (0)203 882 9621
storm@optimumcomms.com
NOTES TO EDITORS
About STORM Therapeutics
STORM Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications to treat disease. Its world leading understanding of RNA modifying enzymes (RME) has led to the discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases.
STORM’s lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors, establishing a data set allowing development in future clinical studies. Preclinical data have revealed that METTL3 inhibition stimulates immune cells and activates interferon pathways, leading to the destruction of tumor cells. Additional preclinical studies have demonstrated enhanced anti-tumor properties in combination with checkpoint inhibitors, supporting clinical development in tumor types where an augmented immune response may result in anti-cancer activity. STORM is building on its first-mover advantage by positioning additional RME inhibitor programs to advance into IND-track activities in 2024. STORM is seeking partners to collaborate and accelerate development of these novel drugs for disease applications outside of oncology.
STORM’s specialist healthcare investors include M Ventures, Pfizer Ventures, Taiho Ventures LLC, Seroba Life Sciences, Cambridge Innovation Capital Limited, IP Group plc, UTokyo Innovation Platform Co., Ltd. and the Fast Track Initiative (FTI).
For more information, please visit www.stormtherapeutics.com
About STC-15
STORM’s lead product, STC-15, is the first RME inhibitor to enter human clinical evaluation. This agent is an oral small molecule that inhibits METTL3, an RNA methyltransferase implicated in oncology and other diseases. Certain RNA methyltransferases are important regulators of RNA sensing and innate immune activation and, as such, represent novel immune-regulatory targets.
STC-15 has also been shown preclinically to inhibit tumor growth through mechanisms involving anti-cancer immune responses, such as changes in interferon signaling and constructive interaction with T cell checkpoint blockade.
STORM is studying the safety and pharmacology of STC-15 in a Phase 1 clinical study in patients with solid tumors. Details of the study can be found on clinicaltrials.gov under the identifier NCT05584111.
About EORTC-NCI-AACR Symposium
The EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics is a scientific meeting that brings together academics, scientists, and pharmaceutical industry leaders to discuss the latest developments in drug development and cancer therapeutics. The conference is a collaboration between the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC).